-
1.
Osteoporosis and Primary Biliary Cholangitis: A Trans-ethnic Mendelian Randomization Analysis.
Wu, Y, Qian, Q, Liu, Q, Wang, R, Pu, X, Li, Y, Zhang, H, You, Z, Miao, Q, Xiao, X, et al
Clinical reviews in allergy & immunology. 2024
Abstract
Osteoporosis is a major clinical problem in many autoimmune diseases, including primary biliary cholangitis (PBC), the most common autoimmune liver disease. Osteoporosis is a major cause of fracture and related mortality. However, it remains unclear whether PBC confers a causally risk-increasing effect on osteoporosis. Herein, we aimed to investigate the causal relationship between PBC and osteoporosis and whether the relationship is independent of potential confounders. We performed bidirectional Mendelian randomization (MR) analyses to investigate the association between PBC (8021 cases and 16,489 controls) and osteoporosis in Europeans (the UK Biobank and FinnGen Consortium: 12,787 cases and 726,996 controls). The direct effect of PBC on osteoporosis was estimated using multivariable MR analyses. An independent replication was conducted in East Asians (PBC: 2495 cases and 4283 controls; osteoporosis: 9794 cases and 168,932 controls). Trans-ethnic meta-analysis was performed by pooling the MR estimates of Europeans and East Asians. Inverse-variance weighted analyses revealed that genetic liability to PBC was associated with a higher risk of osteoporosis in Europeans (OR, 1.040; 95% CI, 1.016-1.064; P = 0.001). Furthermore, the causal effect of PBC on osteoporosis persisted after adjusting for BMI, calcium, lipidemic traits, and sex hormones. The causal relationship was further validated in the East Asians (OR, 1.059; 95% CI, 1.023-1.096; P = 0.001). Trans-ethnic meta-analysis confirmed that PBC conferred increased risk on osteoporosis (OR, 1.045; 95% CI, 1.025-1.067; P = 8.17 × 10-6). Our data supports a causal effect of PBC on osteoporosis, and the causality is independent of BMI, calcium, triglycerides, and several sex hormones.
-
2.
Topical glutathione amino acid precursors protect skin against environmental and oxidative stress.
Cui, X, Mi, T, Xiao, X, Zhang, H, Dong, Y, Huang, N, Gao, P, Lee, J, Guelakis, M, Gu, X
Journal of the European Academy of Dermatology and Venereology : JEADV. 2024;:3-11
Abstract
BACKGROUND Although glutathione (GSH) has long been considered a master antioxidant, poor stability and bioavailability limit its application in skin protection. To overcome the challenges, Unilever R&D formulated a Glutathione Amino acid Precursors blend (named GAP) to boost GSH de novo synthesis. OBJECTIVE Determine whether GAP can boost GSH levels and provide skin protection against stressors. METHODS Normal human epidermal keratinocytes were treated with GAP, with or without stressors, namely, menadione, blue light or pollutants. Ascorbic acid was used as a benchmark. The levels of GSH, glutathione disulfide (GSSG), adenosine triphosphate (ATP) and reactive oxygen species (ROS) were quantified. A placebo-controlled clinical study was conducted on 21 female subjects who received product applications and subsequent UV radiation. Tape strip samples were collected from the subjects for GSH and GSSG quantification using ultra-performance liquid chromatography-mass spectrometry/mass spectrometry (UPLC-MS/MS). The UV-protective effect of GAP was investigated using ex vivo skin. Biomarkers related to DNA damage and the skin barrier were analysed using immunohistochemistry. RESULTS Glutathione amino acid precursors significantly increased the GSH levels and GSH/GSSG ratio in normal human epidermal keratinocytes. Menadione treatment resulted in excessive ROS production and a decline in ATP levels, which were effectively abrogated by GAP. The protective effects of GAP against menadione-induced oxidative stress were superior to those of ascorbic acid. In addition, GAP effectively protected the cells against blue light-induced ROS production and pollutant-induced ATP depletion. Topical application of the GAP formulation significantly elevated the skin GSH/GSSG ratio in a clinical study. Ex vivo skin treated with the GAP formulation displayed a reduction in DNA damage and high levels of barrier proteins after UV exposure. CONCLUSIONS Glutathione amino acid precursors effectively increases cellular GSH levels to protect the skin from oxidative and environmental stresses.
-
3.
Definition of follicular helper T cell and cytokines expression in synovial fluid of rheumatoid arthritis.
Pan, S, Xiao, X, Li, T, Wu, S, Zhou, J, Tan, S, Cheng, J, Tian, Y, Zhang, H, Zhang, X
Clinical rheumatology. 2024;(1):129-135
Abstract
OBJECTIVE This study aimed to assess the role of synovial fluid (SF) CD4+T, CD19+B, follicular helper cells (Tfh), and cytokines in the pathogenesis of rheumatoid arthritis (RA). METHODS This study enrolled 16 patients with RA and 8 patients with osteoarthritis (OA). The frequencies of the SF CD4+ T, CD19+ B, Tfh cells, and Tfh subsets were assessed using flow cytometry. The medical condition in patients with RA was evaluated using The Disease Activity Score 28 (DAS28), the Clinical Disease Activity Index (CDAI), and the Simplified Disease Activity Index (SDAI). Levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), anti-cyclic citrullinated peptide (anti-CCP), and rheumatoid factor (RF) were measured. The cytokines IL-4, IL-13, IL-21, and BLyS were measured by ELISA test. RESULTS The percentages of SF CD4+T, CD19+B, and PD-1+CXCR5+ Tfh in RA patients were higher than those in OA patients. And the Tfh2 was the main subset among Tfh subsets. In addition, levels of IL-21 and BLyS were higher in patients with RA compared to patients with OA. Furthermore, the treatment of TNF-α inhibitors may be associated with decreased levels of SF Tfh. CONCLUSIONS Elevated SF Tfh, B cell, and cytokines expression profiles were observed in RA patients. Tfh2 was the major subset of the Tfh, and IL-21 and BLyS were significantly enhanced. Additionally, TNF-α inhibitors reduced Tfh in SF. Therefore, Tfh, B, and Tfh2 cells could play a significant role in the progression of RA. Key Points •Tfh cells in the synovial fluid are significantly higher in RA patients and are dominated by the Tfh2 subpopulation. •Synovial fluid Tfh cells decrease in RA patients after anti-TNF-α treatment.
-
4.
Therapeutic potential of the medicinal mushroom Ganoderma lucidum against Alzheimer's disease.
Chen, XJ, Deng, Z, Zhang, LL, Pan, Y, Fu, J, Zou, L, Bai, Z, Xiao, X, Sheng, F
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024;:116222
Abstract
Alzheimer's disease (AD) is a high-incidence neurodegenerative disorder, characterized by cognitive impairment, memory loss, and psychiatric abnormalities. Ganoderma lucidum is a famous medicinal fungus with a long history of dietary intake, containing various bioactive components, and have been documented to exhibit antioxidant, anti-inflammatory, anti-tumor, anti-aging, and immunomodulatory effects, among others. Recent studies have shown that G. lucidum and its components have promising therapeutic potential against AD from various aspects, which can delay the progression of AD, improve cognitive function and quality of life. The underlying mechanisms mainly include inhibiting tau hyperphosphorylation, inhibiting Aβ formation, affecting activated microglia, regulating NF-κB/MAPK signalling pathway, inhibiting neuronal apoptosis, modulating immune system, and inhibiting acetylcholinesterase, etc. This paper systematically reviewed the relevant studies on the therapeutic potential of G. lucidum and its active components for treatment of AD, key points related with the mechanism studies and clinical trials have been discussed, and further perspectives have been proposed. Totally, as a natural medicinal mushroom, G. lucidum has the potential to be developed as effective adjuvant for AD treatment owing to its therapeutic efficacy against multiple pathogenesis of AD. Further mechanical investigation and clinical trials can help unlock the complete potential of G. lucidum as a therapeutic option for AD.
-
5.
Current status and prospects of algal bloom early warning technologies: A Review.
Xiao, X, Peng, Y, Zhang, W, Yang, X, Zhang, Z, Ren, B, Zhu, G, Zhou, S
Journal of environmental management. 2024;:119510
Abstract
In recent years, frequent occurrences of algal blooms due to environmental changes have posed significant threats to the environment and human health. This paper analyzes the reasons of algal bloom from the perspective of environmental factors such as nutrients, temperature, light, hydrodynamics factors and others. Various commonly used algal bloom monitoring methods are discussed, including traditional field monitoring methods, remote sensing techniques, molecular biology-based monitoring techniques, and sensor-based real-time monitoring techniques. The advantages and limitations of each method are summarized. Existing algal bloom prediction models, including traditional models and machine learning (ML) models, are introduced. Support Vector Machine (SVM), deep learning (DL), and other ML models are discussed in detail, along with their strengths and weaknesses. Finally, this paper provides an outlook on the future development of algal bloom warning techniques, proposing to combine various monitoring methods and prediction models to establish a multi-level and multi-perspective algal bloom monitoring system, further improving the accuracy and timeliness of early warning, and providing more effective safeguards for environmental protection and human health.
-
6.
Opportunities and challenges in enhancing the bioavailability and bioactivity of dietary flavonoids: A novel delivery system perspective.
Yuan, D, Guo, Y, Pu, F, Yang, C, Xiao, X, Du, H, He, J, Lu, S
Food chemistry. 2024;:137115
Abstract
Flavonoids have multiple favorable bioactivities including antioxidant, anti-inflammatory, and antitumor. Currently, flavonoid-containing dietary supplements are widely tested in clinical trials for the prevention and/or treatment of multiple diseases. However, the clinical application of flavonoids is largely compromised by their low bioavailability and bioactivity, probably due to their poor aqueous solubility, intensive metabolism, and low systemic absorption. Therefore, formulating flavonoids into novel delivery systems is a promising approach for overcoming these drawbacks. In this review, we highlight the opportunities and challenges in the clinical use of dietary flavonoids from the perspective of novel delivery systems. First, the classification, sources, and bioactivity of dietary flavonoids are described. Second, the progress of clinical research on flavonoid-based dietary supplements is systematically summarized. Finally, novel delivery systems developed to improve the bioavailability and bioactivity of flavonoids are discussed in detail to broaden the clinical application of dietary flavonoids.
-
7.
Injectable Fluorescent Neural Interfaces for Cell-Specific Stimulating and Imaging.
Xu, S, Xiao, X, Manshaii, F, Chen, J
Nano letters. 2024
Abstract
Building on current explorations in chronic optical neural interfaces, it is essential to address the risk of photothermal damage in traditional optogenetics. By focusing on calcium fluorescence for imaging rather than stimulation, injectable fluorescent neural interfaces significantly minimize photothermal damage and improve the accuracy of neuronal imaging. Key advancements including the use of injectable microelectronics for targeted electrical stimulation and their integration with cell-specific genetically encoded calcium indicators have been discussed. These injectable electronics that allow for post-treatment retrieval offer a minimally invasive solution, enhancing both usability and reliability. Furthermore, the integration of genetically encoded fluorescent calcium indicators with injectable bioelectronics enables precise neuronal recording and imaging of individual neurons. This shift not only minimizes risks such as photothermal conversion but also boosts safety, specificity, and effectiveness of neural imaging. Embracing these advancements represents a significant leap forward in biomedical engineering and neuroscience, paving the way for advanced brain-machine interfaces.
-
8.
Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases.
Zeng, Y, Wu, Y, Zhang, Q, Xiao, X
mBio. 2024;(1):e0203223
Abstract
Gut microbiota exert influence on gastrointestinal mucosal permeability, bile acid metabolism, short-chain fatty acid synthesis, dietary fiber fermentation, and farnesoid X receptor/Takeda G protein-coupled receptor 5 (TGR5) signal transduction. The incretin glucagon-like peptide 1 (GLP-1) is mainly produced by L cells in the gut and regulates postprandial blood glucose. Changes in gut microbiota composition and function have been observed in obesity and type 2 diabetes (T2D). Meanwhile, the function and rhythm of GLP-1 have also been affected in subjects with obesity or T2D. Therefore, it is necessary to discuss the link between the gut microbiome and GLP-1. In this review, we describe the interaction between GLP-1 and the gut microbiota in metabolic diseases. On the one hand, gut microbiota metabolites stimulate GLP-1 secretion, and gut microbiota affect GLP-1 function and rhythm. On the other hand, the mechanism of action of GLP-1 on gut microbiota involves the inflammatory response. Additionally, we discuss the effects and mechanism of various interventions, such as prebiotics, probiotics, antidiabetic drugs, and bariatric surgery, on the crosstalk between gut microbiota and GLP-1. Finally, we stress that gut microbiota can be used as a target for metabolic diseases, and the clinical application of GLP-1 receptor agonists should be individualized.
-
9.
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.
Mason, M, Lapuente-Santana, Ó, Halkola, AS, Wang, W, Mall, R, Xiao, X, Kaufman, J, Fu, J, Pfeil, J, Banerjee, J, et al
Journal of translational medicine. 2024;(1):190
Abstract
BACKGROUND Predictive biomarkers of immune checkpoint inhibitor (ICI) efficacy are currently lacking for non-small cell lung cancer (NSCLC). Here, we describe the results from the Anti-PD-1 Response Prediction DREAM Challenge, a crowdsourced initiative that enabled the assessment of predictive models by using data from two randomized controlled clinical trials (RCTs) of ICIs in first-line metastatic NSCLC. METHODS Participants developed and trained models using public resources. These were evaluated with data from the CheckMate 026 trial (NCT02041533), according to the model-to-data paradigm to maintain patient confidentiality. The generalizability of the models with the best predictive performance was assessed using data from the CheckMate 227 trial (NCT02477826). Both trials were phase III RCTs with a chemotherapy control arm, which supported the differentiation between predictive and prognostic models. Isolated model containers were evaluated using a bespoke strategy that considered the challenges of handling transcriptome data from clinical trials. RESULTS A total of 59 teams participated, with 417 models submitted. Multiple predictive models, as opposed to a prognostic model, were generated for predicting overall survival, progression-free survival, and progressive disease status with ICIs. Variables within the models submitted by participants included tumor mutational burden (TMB), programmed death ligand 1 (PD-L1) expression, and gene-expression-based signatures. The best-performing models showed improved predictive power over reference variables, including TMB or PD-L1. CONCLUSIONS This DREAM Challenge is the first successful attempt to use protected phase III clinical data for a crowdsourced effort towards generating predictive models for ICI clinical outcomes and could serve as a blueprint for similar efforts in other tumor types and disease states, setting a benchmark for future studies aiming to identify biomarkers predictive of ICI efficacy. TRIAL REGISTRATION CheckMate 026; NCT02041533, registered January 22, 2014. CheckMate 227; NCT02477826, registered June 23, 2015.
-
10.
Correlation between sarcopenia and esophageal cancer: a narrative review.
Li, S, Xie, K, Xiao, X, Xu, P, Tang, M, Li, D
World journal of surgical oncology. 2024;(1):27
Abstract
BACKGROUND In recent years, the research on the relationship between sarcopenia before and after the treatment of esophageal cancer, as well as its impact on prognosis of esophageal cancer, has increased rapidly, which has aroused people's attention to the disease of patients with esophageal cancer complicated with sarcopenia. This review examines the prevalence of sarcopenia in patients with esophageal cancer, as well as the relationship between sarcopenia (before and after surgery or chemotherapy) and prognosis in patients with esophageal cancer. Moreover, we summarized the potential pathogenesis of sarcopenia and pharmacologic and non-pharmacologic therapies. METHODS A narrative review was performed in PubMed and Web of Science using the keywords ("esophageal cancer" or "esophageal neoplasm" or "neoplasm, esophageal" or "esophagus neoplasm" or "esophagus neoplasms" or "neoplasm, esophagus" or "neoplasms, esophagus" or "neoplasms, esophageal" or "cancer of esophagus" or "cancer of the esophagus" or "esophagus cancer" or "cancer, esophagus" or "cancers, esophagus" or "esophagus cancers" or "esophageal cancer" or "cancer, esophageal" or "cancers, esophageal" or "esophageal cancers") and ("sarcopenia" or "muscular atrophy" or "aging" or "senescence" or "biological aging" or "aging, biological" or "atrophies, muscular" or "atrophy, muscular" or "muscular atrophies" or "atrophy, muscle" or "atrophies, muscle" or "muscle atrophies"). Studies reporting relationship between sarcopenia and esophageal cancer were analyzed. RESULTS The results of the review suggest that the average prevalence of sarcopenia in esophageal cancer was 46.3% ± 19.6% ranging from 14.4 to 81% and sarcopenia can be an important predictor of poor prognosis in patients with esophageal cancer. Patients with esophageal cancer can suffer from sarcopenia due to their nutritional deficiencies, reduced physical activity, chemotherapy, and the effects of certain inflammatory factors and pathways. When classic diagnostic values for sarcopenia such as skeletal muscle index (SMI) are not available clinically, it is also feasible to predict esophageal cancer prognosis using simpler metrics, such as calf circumference (CC), five-count sit-up test (5-CST), and six-minute walk distance (6MWD). CONCLUSIONS Identifying the potential mechanism of sarcopenia in patients with esophageal cancer and implementing appropriate interventions may hold the key to improving the prognosis of these patients.